- A +

Gene Therapy Against Blindness

GenSight Biologics is a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. To address these therapeutic areas, we leverage our integrated development platform by combining a gene therapy-based approach with our core technologies of mitochondrial targeting sequence, or MTS, and optogenetics.

Our management and scientific teams have extensive experience in gene therapy and drug development in particular in the field of ophthalmology and have served in leadership roles at several innovative ophthalmology companies. 


 January 7, 2015

GenSight Biologics, Pixium Vision and Fondation Voir et Entendre join forces and benefit from a total € 18.5 million funding for SIGHT AGAIN as part of the Investment for the Future.

This public - private project with an overall budget of € 47 million aims to restore vision to legally blind patients with retinitis pigmentosa at different stages of the disease.

Other news

06 May 2014

GenSight Biologics, a pioneer of innovative gene therapy based solutions to preserve or restore vision in people with degenerative retinal and inherited ophthalmologic diseases, announces the appointment of Jean-Philippe Combal as Chief Operating Officer (“COO”). Dr Combal will lead the Company’s operational activities and the development of its products.

28 April 2013

GenSight Biologics, a biopharmaceutical company focused on the development of ophthalmic therapeutics using gene therapy, announced today the closing of a €32 million Series A financing.


Discover our videos